Retina (Philadelphia, Pa.) · 2025
REAL-WORLD EFFICACY OF INTRAVITREAL METHOTREXATE FOR MANAGING PROLIFERATIVE VITREORETINOPATHY IN RECURRENT RHEGMATOGENOUS RETINAL DETACHMENT.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yun Justin S, Fortes Blake H, Yamamoto Marcus H, Au Adrian C, Prasad Pradeep S, McCannel Colin A, Tsui Irena, McCannel Tara A, Hosseini Hamid, Giral David Lozano, Barzelay-Wollman Aya, Pettenkofer Moritz S, Hou Kirk K
Аннотация
PURPOSE: To evaluate the efficacy of serial intravitreal methotrexate injections as an adjunct to surgical repair in the management of recurrent rhegmatogenous retinal detachment because of proliferative vitreoretinopathy.
METHODS: A retrospective cohort study was conducted involving 41 eyes with a history of failed rhegmatogenous retinal detachment repair presenting with recurrent rhegmatogenous retinal detachment and grade C1 to D proliferative vitreoretinopathy, treated with pars plana vitrectomy and serial methotrexate injections were included, separated into group 1 (with modified Gain Understanding Against Retinal Detachment protocol, n = 27) and group 2 (without modified Gain Understanding Against Retinal Detachment protocol, n = 14). The primary outcome was retinal reattachment rate, and secondary outcomes were changes in visual acuity and postoperative complications.
RESULTS: Retinal reattachment was achieved without additional surgery in 21 (77.8%) eyes in group 1 and 10 (71.4%) in group 2 at final follow-up, with no statistical significance. Improvement in logarithm of the minimal angle of resolution was 0.50 in group 1 and 0.44 in group 2, with a median follow-up of 12.1 months from surgery and no differences in postoperative complications.
CONCLUSION: There were no differences in retinal reattachment or visual acuity outcomes between both methotrexate regimens. The overall reattachment rate exceeded previously reported rates for recurrent rhegmatogenous retinal detachment with proliferative vitreoretinopathy. Further research is needed to optimize the injection protocol for better clinical outcomes.
METHODS: A retrospective cohort study was conducted involving 41 eyes with a history of failed rhegmatogenous retinal detachment repair presenting with recurrent rhegmatogenous retinal detachment and grade C1 to D proliferative vitreoretinopathy, treated with pars plana vitrectomy and serial methotrexate injections were included, separated into group 1 (with modified Gain Understanding Against Retinal Detachment protocol, n = 27) and group 2 (without modified Gain Understanding Against Retinal Detachment protocol, n = 14). The primary outcome was retinal reattachment rate, and secondary outcomes were changes in visual acuity and postoperative complications.
RESULTS: Retinal reattachment was achieved without additional surgery in 21 (77.8%) eyes in group 1 and 10 (71.4%) in group 2 at final follow-up, with no statistical significance. Improvement in logarithm of the minimal angle of resolution was 0.50 in group 1 and 0.44 in group 2, with a median follow-up of 12.1 months from surgery and no differences in postoperative complications.
CONCLUSION: There were no differences in retinal reattachment or visual acuity outcomes between both methotrexate regimens. The overall reattachment rate exceeded previously reported rates for recurrent rhegmatogenous retinal detachment with proliferative vitreoretinopathy. Further research is needed to optimize the injection protocol for better clinical outcomes.